Annals of Surgery · 2004 · 27 citations · 24 references
MedicineOncologyPharmacologyChemotherapyMetastasisMolecular OncologyLiver MetastasisPancreatic Cancer5-Fluorouracil TreatmentImmunohistochemical DetectionImmunohistochemical MarkersImmunohistochemical StainingPancreatic Cancer Liver MetastasisPancreatic Cancer ResectionParaffin-embedded Tissue StainingPerfusion Chemotherapy
In Brief Objective: To clarify the relationship between intratumoral dihydropyrimidine dehydrogenase (DPD) expression and response to 5-fluorouracil (5-FU) liver perfusion chemotherapy (LPC) in pancreatic cancer patients, we evaluated DPD expression immunohistochemically in resected pancreatic cancer tissues. Summary Background Data: Pancreatic cancer is considered a disease with a poor prognosis even if aggressive resection is performed. One of the main causes of death is hepatic metastasis soon after surgery. As a treatment, we have assessed adjuvant LPC via the portal vein using 5-FU just after pancreatectomy for advanced pancreatic cancer since 1994. However, the results remain unsatisfying. Methods: Sixty-eight resected specimens were obtained from patients with pancreatic cancer from 1988 to 2000. Formalin-fixed paraffin-embedded tissues were immunostained with polyclonal anti-DPD antibody. The relation between intratumoral DPD expression and the prognoses of pancreatic cancer patients was investigated statistically. Results: Of the 68 tumors studied, 27 carcinomas (39.7%) were DPD(+), and 41 (60.3%) were DPD(−). In the DPD(+) group, there was no significant difference between the LPC(+) and LPC(−) subgroups, whereas in the DPD(−) group the LPC(+) subgroup showed a significantly higher survival rate than the LPC(−) subgroup. Moreover, in the LPC(+) group, overall survival in the DPD(−) subgroup was significantly better than in the DPD(+) subgroup. Conclusions: An immunohistochemical evaluation of intratumoral DPD expression might be useful in predicting responsiveness to 5-FU-based chemotherapy in pancreatic cancer patients. In the DPD(−) group, liver perfusion chemotherapy using 5-FU via the portal vein is effective adjuvant therapy for pancreatic cancer once pancreatectomy has been performed. Of 68 pancreatic cancer tissues immunostained, 27 carcinomas (39.7%) have expressed dihydropyrimidine dehydrogenase (DPD) antigen. In the DPD(−) group, patients who received adjuvant 5-fluorouracil liver perfusion chemotherapy (LPC) had a better prognosis than those who did not. In the LPC(+) group, patients with DPD(−) tumors had a better prognosis than those with DPD(+) tumors.
24
Howard A. Burris, Malcolm J. Moore, John Sahl Andersen et al. · Journal of Clinical Oncology · 1997 · 5.9K citations
Medicine, Oncology, Pharmacotherapy +16
Dennis Salonga, Kathleen D. Danenberg, Martin R. Johnson et al. · PubMed · 2000 · 834 citations
Tetsuhiko Shirasaka, Yuji Shimamato, Hideyuki Ohshimo et al. · Anti-Cancer Drugs · 1996 · 824 citations
Patterns of failure after curative resection of pancreatic carcinoma
John F. Griffin, Stephen R. Smalley, William R. Jewell et al. · Cancer · 1990 · 437 citations
Recurrence after resection for ductal adenocarcinoma of the pancreas
Cosimo Sperti, Claudio Pasquali, Antonio Piccoli et al. · World Journal of Surgery · 1997 · 435 citations